Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
XOMA Royalty Corp. (XOMA)
USD40.17
+0.00 (+0.00%)
US NASDAQ Healthcare Biotechnology
Address
2200 Powell Street 94608
EmeryVille, CA, US
EmeryVille, CA, US
CEO
Owen Hughes Jr.
Website
xoma.com
IPO
1986-06-06
CIK 791908 ISIN US98419J2069
Also trades on
NASDAQ Global Market · XOMA (USD)
NASDAQ Global Market · XOMAO (USD)
NASDAQ Global Market · XOMAP (USD)
Description
XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main office in Emeryville, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD40.17
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
226.1K
Beta
0.87
Float Shares
11.59M
Free Float %
95.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.12% | +1.21% | +8.15% | +74.09% | +29.65% | +57.20% | +52.06% | +108.37% | +42.71% | +211.94% | -99.18% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (10 ratings, all time)
Buy
Price Targets & DCF
Current price
40.17
Low
39.00
-2.9%
Consensus
53.75
+33.8%
Median
50.00
+24.5%
High
76.00
+89.2%
Ratings Trend (MoM)
40% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | -2 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
39.00
-2.9%
|
| Last Quarter | 2 |
44.50
+10.8%
|
| Last Year | 6 |
59.50
+48.1%
|
| All Time | 6 |
59.50
+48.1%
|
Quality scores
Altman Z-Score
-3.74
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+83.1% ★ Q1'26: -22.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+188.5% ★ Q1'26: +150.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-19.5% Q1'26: +49.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+21.8% ★ Q1'26: -3.9% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+7.4% ★ Q1'26: -1.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+53.7% Q1'26: +18.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×9.16× Q1'26: -64.96× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 1993 actual |
Dec 1995 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 3 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
600.0K
est: 523.2K (+14.7%)
|
1.20M
est: 1.66M (-27.8%)
|
55.45M
est: 11.13M (+398.2%)
|
5.56M
est: 5.78M (-3.7%)
|
52.69M
est: 50.31M (+4.7%)
|
5.30M
est: 4.73M (+12.0%)
|
18.37M
est: 21.22M (-13.4%)
|
29.39M
est: 19.00M (+54.7%)
|
38.16M
est: 37.37M (+2.1%)
|
6.03M
est: 5.60M (+7.6%)
|
4.76M
est: 15.24M (-68.8%)
|
28.49M
est: 28.52M (-0.1%)
|
52.15M
est: 49.42M (+5.5%)
|
60.73M
56.47M – 65.00M
+22.9% YoY
|
52.48M
49.61M – 54.43M
-13.6% YoY
|
61.15M
61.13M – 61.18M
+16.5% YoY
|
69.83M
66.01M – 72.42M
+14.2% YoY
|
79.35M
75.01M – 82.30M
+13.6% YoY
|
| EBITDA |
-31.90M
est: -32.47M (+1.8%)
|
-23.40M
est: -24.30M (+3.7%)
|
-15.31M
est: -2.87M (-434.2%)
|
-48.82M
est: -1.49M (-3,179.7%)
|
20.78M
est: -12.96M (+260.4%)
|
-12.49M
est: -1.22M (-924.7%)
|
-3.86M
est: -5.46M (+29.4%)
|
13.81M
est: -4.89M (+382.3%)
|
16.52M
est: -9.62M (+271.7%)
|
-16.85M
est: -32.01M (+47.4%)
|
-22.56M
est: -4.52M (-399.4%)
|
-5.42M
est: -8.46M (+35.9%)
|
14.36M
est: -14.65M (+198.0%)
|
-18.00M
-19.27M – -16.74M
-22.9% YoY
|
-15.56M
-16.13M – -14.71M
+13.6% YoY
|
-18.13M
-18.14M – -18.12M
-16.5% YoY
|
-20.70M
-21.47M – -19.57M
-14.2% YoY
|
-23.52M
-24.40M – -22.24M
-13.6% YoY
|
| EBIT |
-34.70M
est: -34.90M (+0.6%)
|
-26.30M
est: -28.57M (+7.9%)
|
-16.97M
est: -2.91M (-484.1%)
|
-49.61M
est: -1.51M (-3,187.3%)
|
17.49M
est: -13.13M (+233.2%)
|
-12.56M
est: -1.24M (-916.1%)
|
-3.89M
est: -5.54M (+29.9%)
|
13.64M
est: -4.96M (+375.0%)
|
16.35M
est: -9.75M (+267.6%)
|
-17.12M
est: -29.25M (+41.5%)
|
-23.46M
est: -4.73M (-396.3%)
|
-5.64M
est: -8.85M (+36.3%)
|
11.38M
est: -15.33M (+174.3%)
|
-18.84M
-20.17M – -17.52M
-22.9% YoY
|
-16.28M
-16.89M – -15.39M
+13.6% YoY
|
-18.97M
-18.98M – -18.96M
-16.5% YoY
|
-21.66M
-22.47M – -20.48M
-14.2% YoY
|
-24.62M
-25.53M – -23.27M
-13.6% YoY
|
| Net Income |
-31.30M
est: -31.45M (+0.5%)
|
-22.50M
est: -24.30M (+7.4%)
|
-20.61M
est: -125.98M (+83.6%)
|
-53.53M
est: -82.14M (+34.8%)
|
14.60M
est: 6.71M (+117.6%)
|
-13.34M
est: -20.20M (+34.0%)
|
-1.98M
est: -2.46M (+19.3%)
|
13.30M
est: 2.61M (+408.9%)
|
15.80M
est: 11.94M (+32.4%)
|
-17.10M
est: -30.84M (+44.5%)
|
-40.83M
est: -38.65M (-5.6%)
|
-13.82M
est: -18.66M (+25.9%)
|
31.71M
est: 18.52M (+71.3%)
|
15.00M
-3.76M – 30.94M
-19.0% YoY
|
-900.0K
-1.77M – 62.4K
-106.0% YoY
|
8.10M
7.48M – 8.44M
+1,000.0% YoY
|
12.58M
11.69M – 13.19M
+55.3% YoY
|
22.48M
20.88M – 23.56M
+78.7% YoY
|
| SGA |
35.10M
est: 1.24M (+2,724.1%)
|
5.40M
est: 3.95M (+36.8%)
|
20.62M
est: 26.44M (-22.0%)
|
18.32M
est: 13.73M (+33.4%)
|
24.34M
est: 119.53M (-79.6%)
|
18.56M
est: 11.25M (+65.1%)
|
21.00M
est: 50.41M (-58.3%)
|
16.80M
est: 45.14M (-62.8%)
|
20.46M
est: 88.77M (-77.0%)
|
23.19M
est: 13.30M (+74.3%)
|
27.18M
est: 36.57M (-25.7%)
|
34.48M
est: 68.45M (-49.6%)
|
36.09M
est: 118.60M (-69.6%)
|
145.75M
135.51M – 155.99M
+22.9% YoY
|
125.93M
119.04M – 130.61M
-13.6% YoY
|
146.75M
146.69M – 146.81M
+16.5% YoY
|
167.57M
158.40M – 173.80M
+14.2% YoY
|
190.43M
180.01M – 197.51M
+13.6% YoY
|
| EPS |
-438.00
est: -445.74 (+1.7%)
|
-285.16
est: -387.90 (+26.5%)
|
-3.50
est: -10.77 (+67.5%)
|
-8.89
est: -7.02 (-26.6%)
|
0.75
est: 0.57 (+30.8%)
|
-1.59
est: -1.73 (+7.9%)
|
-0.88
est: -0.21 (-319.0%)
|
0.82
est: 0.22 (+267.2%)
|
0.69
est: 1.02 (-32.4%)
|
-1.98
est: -1.97 (-0.8%)
|
-4.04
est: -2.17 (-85.8%)
|
-1.65
est: -1.04 (-59.0%)
|
1.53
est: 1.17 (+31.3%)
|
0.79
-0.21 – 1.72
-32.6% YoY
|
-0.05
-0.10 – 0.00
-106.1% YoY
|
0.45
0.42 – 0.47
+1,034.7% YoY
|
0.70
0.65 – 0.73
+56.3% YoY
|
1.25
1.16 – 1.31
+78.7% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-30 | HC Wainwright & Co. | Buy | Neutral | Downgrade |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-01 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
3.15M
OE per share TTM
0.21
Owner's Yield
0.42%
Maintenance CapEx ratio
1.03%
Maint CapEx / Avg PPE
1.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
28
Total invested
35.90M
Insider transactions (90d)
4
Beneficial owners (>5%)
38
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 13-4093645 | 30.65M | 26.80% | 30.65M | — | 30.65M | 10.00 | IA, PN | Delaware | 2014-05-28 | ↗ |
| 2 | 46-3147749 | 30.65M | 26.80% | 30.65M | — | 30.65M | 10.00 | HC, OO | Delaware | 2014-05-28 | ↗ |
| 3 | Felix J. Baker | 30.65M | 26.80% | 30.65M | — | 30.65M | 10.00 | HC, IN | United States | 2014-05-28 | ↗ |
| 4 | Julian C. Baker | 30.65M | 26.80% | 30.65M | — | 30.65M | 10.00 | HC, IN | United States | 2014-05-28 | ↗ |
| 5 | Edward C. Johnson 3d | 12.24M | 11.77% | — | — | 12.24M | — | IN | United States of America | 2014-02-14 | ↗ |
| 6 | 13G | 8.09M | 13.02% | 8.09M | — | 8.09M | — | CO | State of Delaware | 2018-04-30 | ↗ |
| 7 | Kingdon Capital Management, L.L.C. | 8.04M | 6.97% | — | 8.04M | — | 8.04M | IA | Delaware | 2015-02-17 | ↗ |
| 8 | Mark Kingdon | 8.04M | 6.97% | — | 8.04M | — | 8.04M | HC, IN | Delaware | 2015-02-17 | ↗ |
| 9 | Capital Ventures International | 7.24M | 6.30% | — | 7.24M | — | — | CO | Cayman Islands | 2014-12-17 | ↗ |
| 10 | Heights Capital Management, Inc. | 7.24M | 6.30% | — | 7.24M | — | — | CO | Cayman Islands | 2014-12-17 | ↗ |
| 11 | Peter Kolchinsky | 6.70M | 8.20% | 6.70M | — | 6.70M | — | IN | United States | 2013-02-14 | ↗ |
| 12 | RA Capital Management, LLC | 6.70M | 8.20% | 6.70M | — | 6.70M | — | IA | Massachusetts | 2013-02-14 | ↗ |
| 13 | Deerfield Management Company, L.P. | 6.15M | 6.70% | — | 6.15M | — | — | PN | Delaware | 2013-08-29 | ↗ |
| 14 | Deerfield Mgmt, L.P. | 6.15M | 6.70% | — | 6.15M | — | — | PN | Delaware | 2013-08-29 | ↗ |
| 15 | James E. Flynn | 6.15M | 6.70% | — | 6.15M | — | — | IN | Delaware | 2013-08-29 | ↗ |
| 16 | RA Capital Healthcare Fund, L.P. | 3.92M | 4.80% | 3.92M | — | 3.92M | — | PN | Delaware | 2013-02-14 | ↗ |
| 17 | BVF INC. | 3.90M | 35.40% | — | — | — | 3.90M | CO | — | 2020-02-13 | ↗ |
| 18 | BVF PARTNERS L.P. | 3.90M | 35.40% | — | — | — | 3.90M | IA, PN | — | 2020-02-13 | ↗ |
| 19 | MARK N. LAMPERT | 3.90M | 35.40% | — | — | — | 3.90M | IN | — | 2020-02-13 | ↗ |
| 20 | BVF GP HOLDINGS LLC | 3.50M | 31.80% | — | — | — | 3.50M | OO | — | 2020-02-13 | ↗ |
| 21 | Deerfield International Master Fund, L.P. | 2.07M | 2.26% | — | 2.07M | — | — | PN | Delaware | 2013-08-29 | ↗ |
| 22 | BIOTECHNOLOGY VALUE FUND, L.P. | 1.80M | 17.30% | — | — | — | 1.80M | PN | — | 2020-02-13 | ↗ |
| 23 | BVF I GP LLC | 1.80M | 17.30% | — | — | — | 1.80M | OO | — | 2020-02-13 | ↗ |
| 24 | BIOTECHNOLOGY VALUE FUND II, L.P. | 1.70M | 16.40% | — | — | — | 1.70M | PN | — | 2020-02-13 | ↗ |
| 25 | BVF II GP LLC | 1.70M | 16.40% | — | — | — | 1.70M | OO | — | 2020-02-13 | ↗ |
| 26 | Deerfield Partners, L.P. | 1.61M | 1.75% | — | 1.61M | — | — | PN | Delaware | 2013-08-29 | ↗ |
| 27 | Deerfield Special Situations Fund, L.P. | 1.35M | 1.47% | — | 1.35M | — | — | PN | Delaware | 2013-08-29 | ↗ |
| 28 | Abigail P. Johnson | 1.16M | 10.18% | — | — | 1.16M | — | IN | Delaware | 2022-08-10 | ↗ |
| 29 | FMR LLC | 1.16M | 10.18% | 1.16M | — | 1.16M | — | HC | Delaware | 2022-08-10 | ↗ |
| 30 | Deerfield Special Situations International Master Fund, L.P. | 1.12M | 1.22% | — | 1.12M | — | — | PN | Delaware | 2013-08-29 | ↗ |
| 31 | Novartis AG | 539.1K | 6.60% | — | 539.1K | — | — | CO | Switzerland | 2017-09-05 | ↗ |
| 32 | Novartis Pharma AG | 539.1K | 6.60% | — | 539.1K | — | — | CO | Switzerland | 2017-09-05 | ↗ |
| 33 | (1) BlackRock, Inc. | 508.7K | 6.10% | 498.9K | — | 508.7K | — | HC | Delaware | 2019-02-08 | ↗ |
| 34 | BIOTECHNOLOGY VALUE TRADING FUND OS, L.P. | 159.5K | 1.60% | — | — | — | 159.5K | PN | — | 2020-02-13 | ↗ |
| 35 | BVF PARTNERS OS LTD. | 159.5K | 1.60% | — | — | — | 159.5K | CO | — | 2020-02-13 | ↗ |
| 36 | Eagle Point Credit Management LLC | 149.2K | 6.30% | 149.2K | — | 149.2K | — | IA | Delaware | 2021-04-19 | ↗ |
| 37 | MATTHEW D. PERRY | 36.8K | 1.00% | — | — | 36.8K | — | IN | — | 2020-02-13 | ↗ |
| 38 | Biotechnology Value Trading Fund OS LP | 26.5K | 1.00% | — | 26.5K | — | — | PN | Delaware | 2016-11-18 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
28
-46 vs prev Q
New positions
7
Closed positions
53
Increased
15
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | 15.0K +15.0K (+100.0%) | 398.85M +398.9M (+100.0%) | 0.12% +0.124 pp | 0.34% +0.340 pp | USD26.59 +0.0% | 1 qtrs NEW |
| 2 | BVF INC/IL | 2.59M +— (+0.0%) | 68.88M -31.0M (-31.0%) | 21.34% -0.231 pp | 2.32% -1.728 pp | USD16.10 +65.2% | 37 qtrs — |
| 3 | MORGAN STANLEY | 1.71M +67.7K (+4.1%) | 45.59M -17.9M (-28.2%) | 14.13% +0.411 pp | 0.00% -0.001 pp | USD23.63 +12.5% | 37 qtrs — |
| 4 | FMR LLC | 1.16M +87.6K (+8.2%) | 30.89M -10.5M (-25.4%) | 9.57% +0.626 pp | 0.00% -0.001 pp | USD32.14 -17.3% | 20 qtrs — |
| 5 | VANGUARD GROUP INC | 701.7K +33.5K (+5.0%) | 18.66M -7.1M (-27.5%) | 5.78% +0.217 pp | 0.00% 0.000 pp | USD23.46 +13.3% | 37 qtrs — |
| 6 | BLACKROCK, INC. | 611.5K +18.6K (+3.1%) | 16.26M -6.6M (-28.8%) | 5.04% +0.101 pp | 0.00% 0.000 pp | USD26.38 +0.8% | 6 qtrs — |
| 7 | OPALEYE MANAGEMENT INC. | 292.6K +37.5K (+14.7%) | 7.78M -2.1M (-20.9%) | 2.41% +0.286 pp | 1.03% -0.364 pp | USD13.40 +98.4% | 36 qtrs — |
| 8 | WOODLINE PARTNERS LP | 262.9K +53.0K (+25.2%) | 6.99M -1.1M (-13.6%) | 2.17% +0.418 pp | 0.03% -0.011 pp | USD25.82 +3.0% | 9 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 221.6K +9.6K (+4.5%) | 5.89M -2.3M (-27.9%) | 1.83% +0.060 pp | 0.00% 0.000 pp | USD23.79 +11.8% | 37 qtrs — |
| 10 | STATE STREET CORP | 174.9K +7.9K (+4.7%) | 4.65M -1.8M (-27.8%) | 1.44% +0.050 pp | 0.00% 0.000 pp | USD23.72 +12.1% | 23 qtrs — |
| 11 | STONEPINE CAPITAL MANAGEMENT, LLC | 115.0K -459.0 (-0.4%) | 3.06M -1.4M (-31.3%) | 0.95% -0.014 pp | 2.23% -1.385 pp | USD20.29 +31.0% | 28 qtrs — |
| 12 | HIGHVISTA STRATEGIES LLC | 112.9K +7.2K (+6.8%) | 3.00M -1.1M (-26.3%) | 0.93% +0.050 pp | 0.77% -0.226 pp | USD21.01 +26.6% | 12 qtrs — |
| 13 | NORTHERN TRUST CORP | 90.4K -4.9K (-5.2%) | 2.40M -1.3M (-34.6%) | 0.74% -0.049 pp | 0.00% 0.000 pp | USD21.24 +25.2% | 34 qtrs — |
| 14 | BANK OF NEW YORK MELLON CORP | 68.4K +7.0K (+11.5%) | 1.82M -546.1K (-23.1%) | 0.56% +0.053 pp | 0.00% 0.000 pp | USD21.51 +23.6% | 32 qtrs — |
| 15 | TLS ADVISORS LLC | 47.9K -66.9K (-58.3%) | 1.69M -2.1M (-55.4%) | 0.39% -0.562 pp | 4.43% -6.576 pp | USD18.40 +44.5% | 13 qtrs — |
| 16 | DIMENSIONAL FUND ADVISORS LP | 43.3K +14.1K (+48.5%) | 1.15M +28.2K (+2.5%) | 0.36% +0.114 pp | 0.00% +0.000 pp | USD22.36 +18.9% | 16 qtrs — |
| 17 | CM MANAGEMENT, LLC | 40.0K -8.0K (-16.7%) | 1.06M -786.3K (-42.5%) | 0.33% -0.070 pp | 0.90% -0.646 pp | USD18.70 +42.2% | 9 qtrs — |
| 18 | RENAISSANCE TECHNOLOGIES LLC | 39.0K +10.1K (+35.0%) | 1.04M -76.3K (-6.9%) | 0.32% +0.081 pp | 0.00% +0.000 pp | USD31.73 -16.2% | 6 qtrs — |
| 19 | RBF CAPITAL, LLC | 30.0K -616.0 (-2.0%) | 797.7K -382.2K (-32.4%) | 0.25% -0.008 pp | 0.04% -0.017 pp | USD16.84 +57.9% | 27 qtrs — |
| 20 | WELLINGTON MANAGEMENT GROUP LLP | 29.6K -3.0K (-9.3%) | 786.8K -470.2K (-37.4%) | 0.24% -0.028 pp | 0.00% 0.000 pp | USD38.54 -31.0% | 2 qtrs — |
| 21 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 29.4K +— (+0.0%) | 781.1K -351.0K (-31.0%) | 0.24% -0.003 pp | 0.00% 0.000 pp | USD22.38 +18.8% | 11 qtrs — |
| 22 | UBS GROUP AG | 26.0K +21.9K (+527.5%) | 692.6K +532.6K (+332.9%) | 0.21% +0.180 pp | 0.00% +0.000 pp | USD26.29 +1.1% | 37 qtrs — |
| 23 | LOS ANGELES CAPITAL MANAGEMENT LLC | 19.3K +4.7K (+31.7%) | 642.2K +76.6K (+13.5%) | 0.16% +0.037 pp | 0.00% +0.000 pp | USD25.53 +4.2% | 5 qtrs — |
| 24 | PANAGORA ASSET MANAGEMENT INC | 21.2K +4.1K (+24.2%) | 564.5K -94.3K (-14.3%) | 0.17% +0.033 pp | 0.00% -0.001 pp | USD25.47 +4.4% | 3 qtrs — |
| 25 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 17.6K -7.4K (-29.6%) | 467.5K -495.3K (-51.4%) | 0.14% -0.063 pp | 0.01% -0.011 pp | USD21.08 +26.1% | 12 qtrs — |
| 26 | GOLDMAN SACHS GROUP INC | 16.1K +8.0K (+99.4%) | 428.0K +116.8K (+37.6%) | 0.13% +0.065 pp | 0.00% +0.000 pp | USD32.58 -18.4% | 6 qtrs — |
| 27 | BARCLAYS PLC | 14.8K +3.6K (+31.7%) | 394.1K +96.1K (+32.2%) | 0.12% +0.028 pp | 0.00% +0.000 pp | USD25.34 +4.9% | 11 qtrs — |
| 28 | NUVEEN, LLC | 12.7K +— (+0.0%) | 337.9K -151.8K (-31.0%) | 0.10% -0.001 pp | 0.00% +0.000 pp | USD19.93 +33.4% | 4 qtrs — |
| 29 | BANK OF AMERICA CORP /DE/ | 11.9K +8.0K (+201.9%) | 317.5K +165.1K (+108.3%) | 0.10% +0.066 pp | 0.00% +0.000 pp | USD25.42 +4.6% | 37 qtrs — |
| 30 | RHUMBLINE ADVISERS | 11.6K -1.6K (-12.0%) | 308.0K -199.6K (-39.3%) | 0.10% -0.014 pp | 0.00% 0.000 pp | USD21.33 +24.7% | 11 qtrs — |
| 31 | WELLS FARGO & COMPANY/MN | 10.8K +4.3K (+66.0%) | 286.0K +36.4K (+14.6%) | 0.09% +0.035 pp | 0.00% +0.000 pp | USD25.74 +3.3% | 37 qtrs — |
| 32 | — | 10.0K +10.0K (+100.0%) | 265.9K +265.9K (+100.0%) | 0.08% +0.082 pp | 0.06% +0.062 pp | USD26.59 +0.0% | 1 qtrs NEW |
| 33 | TWO SIGMA INVESTMENTS, LP | 9.7K +9.7K (+100.0%) | 258.3K +258.3K (+100.0%) | 0.08% +0.080 pp | 0.00% +0.000 pp | USD26.59 +0.0% | 1 qtrs NEW |
| 34 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 9.6K +9.6K (+100.0%) | 255.1K +255.1K (+100.0%) | 0.08% +0.079 pp | 0.00% +0.000 pp | USD26.59 +0.0% | 4 qtrs — |
| 35 | SQUAREPOINT OPS LLC | 8.9K +8.9K (+100.0%) | 236.7K +236.7K (+100.0%) | 0.07% +0.073 pp | 0.00% +0.000 pp | USD26.59 +0.0% | 1 qtrs NEW |
| 36 | SG AMERICAS SECURITIES, LLC | 6.4K +6.4K (+100.0%) | 169.0K +169.0K (+100.0%) | 0.05% +0.052 pp | 0.00% +0.000 pp | USD26.59 +0.0% | 1 qtrs NEW |
| 37 | METLIFE INVESTMENT MANAGEMENT, LLC | 5.7K +— (+0.0%) | 151.0K -67.8K (-31.0%) | 0.05% -0.001 pp | 0.00% 0.000 pp | USD26.10 +1.9% | 11 qtrs — |
| 38 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 4.5K +186.0 (+4.3%) | 119.6K -46.6K (-28.0%) | 0.04% +0.001 pp | 0.00% 0.000 pp | USD25.16 +5.7% | 7 qtrs — |
| 39 | JPMORGAN CHASE & CO | 3.8K +39.0 (+1.0%) | 102.0K -44.3K (-30.3%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD24.43 +8.8% | 12 qtrs — |
| 40 | ADVISOR GROUP HOLDINGS, INC. | 3.5K -10.0 (-0.3%) | 94.2K -22.4K (-19.2%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD26.32 +1.0% | 24 qtrs — |
| 41 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 2.9K +— (+0.0%) | 75.9K -34.1K (-31.0%) | 0.02% 0.000 pp | 0.00% 0.000 pp | USD31.61 -15.9% | 5 qtrs — |
| 42 | NEW YORK STATE COMMON RETIREMENT FUND | 2.4K +— (+0.0%) | 62.8K -28.2K (-31.0%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD21.63 +22.9% | 11 qtrs — |
| 43 | BNP PARIBAS ARBITRAGE, SNC | 2.2K -1.1K (-33.3%) | 57.2K -67.1K (-54.0%) | 0.02% -0.009 pp | 0.00% +0.000 pp | USD34.68 -23.3% | 36 qtrs — |
| 44 | ROYAL BANK OF CANADA | 1.2K -285.0 (-18.7%) | 33.0K -26.0K (-44.1%) | 0.01% -0.003 pp | 0.00% +0.000 pp | USD25.09 +6.0% | 37 qtrs — |
| 45 | STATE OF ALASKA, DEPARTMENT OF REVENUE | 1.1K +1.1K (+100.0%) | 27.0K +27.0K (+100.0%) | 0.01% +0.009 pp | 0.00% +0.000 pp | USD26.59 +0.0% | 1 qtrs NEW |
| 46 | LEGAL & GENERAL GROUP PLC | 976.00 +— (+0.0%) | 26.0K -11.7K (-31.0%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD21.67 +22.7% | 11 qtrs — |
| 47 | AMERITAS INVESTMENT PARTNERS, INC. | 959.00 +— (+0.0%) | 25.5K -11.5K (-31.0%) | 0.01% 0.000 pp | 0.00% 0.000 pp | USD21.23 +25.2% | 11 qtrs — |
| 48 | RUSSELL INVESTMENTS GROUP, LTD. | 778.00 +— (+0.0%) | 20.7K -9.3K (-31.0%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD38.16 -30.3% | 7 qtrs — |
| 49 | COSTELLO ASSET MANAGEMENT, INC | 600.00 +— (+0.0%) | 16.0K -7.2K (-31.0%) | 0.00% 0.000 pp | 0.01% -0.003 pp | USD19.93 +33.4% | 4 qtrs — |
| 50 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 585.00 +2.0 (+0.3%) | 15.6K -6.9K (-30.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD18.95 +40.3% | 11 qtrs — |
| 51 | CITIGROUP INC | 555.00 +239.0 (+75.6%) | 14.8K +2.6K (+21.2%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD25.77 +3.2% | 31 qtrs — |
| 52 | TOWER RESEARCH CAPITAL LLC (TRC) | 469.00 +61.0 (+15.0%) | 12.5K -3.3K (-20.7%) | 0.00% +0.001 pp | 0.00% 0.000 pp | USD24.53 +8.4% | 37 qtrs — |
| 53 | NATIXIS | 372.00 +— (+0.0%) | 9.9K -4.4K (-31.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD18.40 +44.5% | 13 qtrs — |
| 54 | FEDERATED HERMES, INC. | 335.00 +108.0 (+47.6%) | 8.9K +159.0 (+1.8%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD34.68 -23.3% | 2 qtrs — |
| 55 | AMALGAMATED BANK | 298.00 +51.0 (+20.6%) | 8.0K -2.0K (-20.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD20.20 +31.6% | 11 qtrs — |
| 56 | TRUVESTMENTS CAPITAL LLC | 290.00 +— (+0.0%) | 7.7K -3.5K (-31.0%) | 0.00% +0.000 pp | 0.00% -0.001 pp | USD26.48 +0.4% | 23 qtrs — |
| 57 | STERLING CAPITAL MANAGEMENT LLC | 233.00 +27.0 (+13.1%) | 6.2K -1.7K (-22.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD32.04 -17.0% | 6 qtrs — |
| 58 | SIMPLEX TRADING, LLC | 173.00 +2.0 (+1.2%) | 4.6K -1.4K (-23.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD38.40 -30.8% | 2 qtrs — |
| 59 | CWM, LLC | 134.00 -18.0 (-11.8%) | 4.0K -2.0K (-33.3%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD28.00 -5.0% | 17 qtrs — |
| 60 | DEUTSCHE BANK AG\ | 124.00 -8.4K (-98.5%) | 3.3K -323.4K (-99.0%) | 0.00% -0.070 pp | 0.00% 0.000 pp | USD21.28 +25.0% | 9 qtrs — |
| 61 | GAMMA INVESTING LLC | 113.00 +11.0 (+10.8%) | 3.0K -926.0 (-23.6%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD25.50 +4.3% | 9 qtrs — |
| 62 | EVERSOURCE WEALTH ADVISORS, LLC | 69.00 -10.0 (-12.7%) | 1.8K -1.2K (-39.7%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD25.19 +5.6% | 3 qtrs — |
| 63 | OPTIVER HOLDING B.V. | 66.00 -84.0 (-56.0%) | 1.8K -4.0K (-69.6%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD38.53 -31.0% | 2 qtrs — |
| 64 | ANCORA ADVISORS, LLC | 31.00 +— (+0.0%) | 824.00 -371.0 (-31.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD38.52 -31.0% | 2 qtrs — |
| 65 | PNC FINANCIAL SERVICES GROUP, INC. | 25.00 +18.0 (+257.1%) | 666.00 +395.0 (+145.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD28.28 -6.0% | 9 qtrs — |
| 66 | NISA INVESTMENT ADVISORS, LLC | 19.00 +— (+0.0%) | 505.00 -227.0 (-31.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD24.11 +10.3% | 11 qtrs — |
| 67 | SBI SECURITIES CO., LTD. | 12.00 -1.0 (-7.7%) | 319.00 -182.0 (-36.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD26.58 +0.0% | 5 qtrs — |
| 68 | ALLWORTH FINANCIAL LP | 10.00 +10.0 (+100.0%) | 266.00 +266.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD26.50 +0.3% | 1 qtrs NEW |
| 69 | ROTHSCHILD INVESTMENT LLC | 3.00 +— (+0.0%) | 80.00 -36.0 (-31.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD19.67 +35.2% | 4 qtrs — |
| 70 | TRUE WEALTH DESIGN, LLC | 3.00 +— (+0.0%) | 80.00 -36.0 (-31.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD19.67 +35.2% | 4 qtrs — |
| 71 | SRS CAPITAL ADVISORS, INC. | 3.00 -44.0 (-93.6%) | 80.00 -1.7K (-95.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD38.33 -30.6% | 2 qtrs — |
| 72 | IFP ADVISORS, INC | 1.00 +— (+0.0%) | 27.00 -12.0 (-30.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD38.00 -30.0% | 2 qtrs — |
| 73 | TD WATERHOUSE CANADA INC. | 1.00 +— (+0.0%) | 27.00 -12.0 (-30.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD24.00 +10.8% | 17 qtrs — |
| 74 | MAN GROUP PLC | — -6.4K (-100.0%) | — -246.5K (-100.0%) | 0.00% -0.053 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 75 | STATE OF WISCONSIN INVESTMENT BOARD | — -13.6K (-100.0%) | — -523.0K (-100.0%) | 0.00% -0.113 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 76 | ADVISORY SERVICES NETWORK, LLC | — -1.0 (-100.0%) | — -39.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 77 | TORTOISE INVESTMENT MANAGEMENT, LLC | — -2.0 (-100.0%) | — -77.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 78 | CITADEL ADVISORS LLC | — -7.6K (-100.0%) | — -292.2K (-100.0%) | 0.00% -0.063 pp | 0.00% +0.000 pp | USD— | 15 qtrs SOLD |
| 79 | JANE STREET GROUP, LLC | — -27.4K (-100.0%) | — -1.1M (-100.0%) | 0.00% -0.228 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 80 | QUADRANT CAPITAL GROUP LLC | — -35.0 (-100.0%) | — -1.3K (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 81 | WEALTHSPIRE ADVISORS, LLC | — -100.0 (-100.0%) | — -3.9K (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 82 | MACQUARIE GROUP LTD | — -6.9K (-100.0%) | — -221.0K (-100.0%) | 0.00% -0.058 pp | 0.00% 0.000 pp | USD— | 37 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 45 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.09% | 1.38M | 0.60% |
| 2 | WisdomTree U.S. SmallCap Fund EES | 0.05% | 339.9K | 0.38% |
| 3 | U.S. Micro Cap Portfolio ETF DFMC | 0.02% | 1.59M | 0.43% |
| 4 | iShares Russell 2000 Growth ETF IWO | 0.02% | 2.93M | 0.24% |
| 5 | Vanguard Russell 2000 Growth ETF VTWG | 0.02% | 267.6K | 0.06% |
| 6 | iShares Russell 2000 BuyWrite ETF IWMW | 0.01% | 7.5K | 0.39% |
| 7 | iShares Russell 2000 ETF IWM | 0.01% | 10.94M | 0.19% |
| 8 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.01% | 71.4K | 0.36% |
| 9 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.01% | 41.8K | 0.25% |
| 10 | Global X - Russell 2000 ETF RSSL | 0.01% | 190.9K | 0.08% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.83
Neutral
Ratio by volume
0.95
Neutral
Buys
5
Sells
6
Shares acquired
33.2K
Shares disposed
34.8K
Cash buys
—
Cash sales
—
Net activity
-1,632
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-20 | Trigilio Jeffrey | Officer | M-Exempt | D | Performance Stock Units | 11,538 | 0.00 | — | 126,924 | D | ↗ |
| 2026-04-20 | Sitko Bradley | Officer | M-Exempt | A | Common Stock | 3,737 | 0.00 | — | 82,961 | D | ↗ |
| 2026-04-20 | Montano Maricel Perea | Officer | M-Exempt | A | Common Stock | 3,370 | 0.00 | — | 41,793 | D | ↗ |
| 2026-04-20 | Hughes Owen | Director / Officer | M-Exempt | A | Common Stock | 10,568 | 0.00 | — | 191,264 | D | ↗ |
| 2026-04-13 | Trigilio Jeffrey | Officer | M-Exempt | D | Performance Stock Units | 4,000 | 0.00 | — | 26,000 | D | ↗ |
| 2026-03-27 | LIMBER JOSEPH M | Director | M-Exempt | A | Common Stock | 3,026 | 11.20 | 33.9K | 9,234 | D | ↗ |
| 2026-03-24 | WYSZOMIERSKI JACK L | Director | M-Exempt | A | Common Stock | 3,026 | 11.20 | 33.9K | 21,530 | D | ↗ |
| 2026-03-16 | Hughes Owen | Director / Officer | A-Award | A | Common Stock | 82,428 | 0.00 | — | 180,696 | D | ↗ |
| 2026-03-11 | Trigilio Jeffrey | Officer | A-Award | A | Performance Stock Units | 138,462 | 0.00 | — | 138,462 | D | ↗ |
| 2026-03-11 | Sitko Bradley | Officer | A-Award | A | Performance Stock Units | 44,849 | 0.00 | — | 44,849 | D | ↗ |
| 2026-03-11 | Montano Maricel Perea | Officer | A-Award | A | Common Stock | 26,289 | 0.00 | — | 38,423 | D | ↗ |
| 2026-01-12 | Trigilio Jeffrey | Officer | A-Award | A | Performance Stock Units | 30,000 | 0.00 | — | 30,000 | D | ↗ |
| 2025-12-04 | Hughes Owen | Director / Officer | P-Purchase | A | Depositary Shares - 8.375% B Cumulative Stock | 100,000 | 25.05 | 2.51M | 102,000 | D | ↗ |
| 2025-09-22 | BURNS THOMAS M. | Officer | S-Sale | D | Common Stock | 15 | 36.81 | 552.15 | 30,079 | D | ↗ |
| 2025-09-19 | Sitko Bradley | Officer | M-Exempt | A | Common Stock | 6,712 | 0.00 | — | 19,822 | D | ↗ |
| 2025-09-19 | Montano Maricel Perea | Officer | M-Exempt | D | Performance Stock Units | 3,033 | 0.00 | — | 11,316 | D | ↗ |
| 2025-09-19 | Hughes Owen | Director / Officer | M-Exempt | A | Common Stock | 35,567 | 0.00 | — | 98,268 | D | ↗ |
| 2025-09-19 | BURNS THOMAS M. | Officer | M-Exempt | A | Common Stock | 11,846 | 0.00 | — | 34,409 | D | ↗ |
| 2025-09-10 | Montano Maricel Perea | Officer | M-Exempt | D | Performance Stock Units | 9,101 | 0.00 | — | 14,349 | D | ↗ |
| 2025-08-12 | Montano Maricel Perea | Officer | A-Award | A | Performance Stock Units | 23,450 | 0.00 | — | 23,450 | D | ↗ |
| 2025-06-30 | Sitko Bradley | Officer | P-Purchase | A | Depositary Shares - 8.375% Series B Cumulative Stock | 2,000 | 25.39 | 50.8K | 7,045 | D | ↗ |
| 2025-05-21 | WYSZOMIERSKI JACK L | Director | A-Award | A | Common Stock | 5,971 | 0.00 | — | 18,504 | D | ↗ |
| 2025-05-21 | PERRY MATTHEW D | Director | A-Award | A | Common Stock | 5,971 | 0.00 | — | 23,840 | D | ↗ |
| 2025-05-21 | LIMBER JOSEPH M | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 9,936 | 25.12 | 249.6K | 9,936 | D | ↗ |
| 2025-05-21 | Kosacz Barbara | Director | A-Award | A | Common Stock | 5,971 | 0.00 | — | 5,971 | D | ↗ |
| 2025-05-21 | Hernday Natasha | Director | A-Award | A | Common Stock | 5,971 | 0.00 | — | 9,006 | D | ↗ |
| 2025-05-21 | Franklin Heather L | Director | A-Award | A | Common Stock | 5,971 | 0.00 | — | 5,971 | D | ↗ |
| 2025-05-20 | Hughes Owen | Director / Officer | S-Sale | D | Common Stock | 25,637 | 25.38 | 650.7K | 62,701 | D | ↗ |
| 2025-05-20 | BURNS THOMAS M. | Officer | S-Sale | D | Common Stock | 10,482 | 25.38 | 266.0K | 22,563 | D | ↗ |
| 2025-05-19 | Hughes Owen | Director / Officer | M-Exempt | D | Performance Stock Units | 53,359 | 0.00 | — | 168,281 | D | ↗ |
| 2025-05-19 | BURNS THOMAS M. | Officer | M-Exempt | D | Performance Stock Units | 17,773 | 0.00 | — | 56,054 | D | ↗ |
| 2025-05-16 | BVF PARTNERS L P/IL | 10% Owner | S-Sale | D | Common Stock, $0.0075 par value per share | 127,407 | 27.10 | 3.45M | 1,322,758 | D | ↗ |
| 2025-04-07 | Sitko Bradley | Officer | P-Purchase | A | Depositary Shares - 8.375% Series B Cumulative Stock | 2,000 | 24.70 | 49.4K | 5,045 | D | ↗ |
| 2025-04-07 | LIMBER JOSEPH M | Director | P-Purchase | A | 8.625% Series A Cumulative Perpetual Preferred Stock | 5,243 | 25.60 | 134.2K | 10,000 | D | ↗ |
| 2025-04-04 | LIMBER JOSEPH M | Director | P-Purchase | A | Depositary Shares - 8.375% Series B Cumulative Stock | 3,476 | 25.25 | 87.8K | 20,000 | D | ↗ |
| 2025-04-03 | LIMBER JOSEPH M | Director | P-Purchase | A | Depositary Shares - 8.375% Series B Cumulative Stock | 16,524 | 25.22 | 416.7K | 16,524 | D | ↗ |
| 2025-04-01 | BURNS THOMAS M. | Officer | P-Purchase | A | Depositary Shares - 8.375% B Cumulative Stock | 1,000 | 25.46 | 25.5K | 2,000 | D | ↗ |
| 2025-03-31 | Sitko Bradley | Officer | P-Purchase | A | Common Stock | 1,000 | 19.98 | 20.0K | 11,484 | D | ↗ |
| 2025-03-21 | Sitko Bradley | Officer | P-Purchase | A | Common Stock | 1,334 | 20.65 | 27.5K | 10,484 | D | ↗ |
| 2025-01-24 | BVF PARTNERS L P/IL | 10% Owner | S-Sale | D | Common Stock, $0.0075 par value per share | 339,679 | 26.10 | 8.87M | 1,450,165 | D | ↗ |
| 2025-01-08 | Sitko Bradley | Officer | P-Purchase | A | 8.625% Series A Cumulative Perpetual Preferred Stock | 82 | 25.60 | 2.1K | 82 | I | ↗ |
| 2024-12-31 | Sitko Bradley | Officer | P-Purchase | A | Common Stock | 300 | 25.90 | 7.8K | 9,150 | D | ↗ |
| 2024-11-13 | Hughes Owen | Director / Officer | S-Sale | D | Common Stock | 21,881 | 29.95 | 655.3K | 34,979 | D | ↗ |
| 2024-11-13 | BURNS THOMAS M. | Officer | S-Sale | D | Common Stock | 9,775 | 29.94 | 292.7K | 14,553 | D | ↗ |
| 2024-11-11 | Hughes Owen | Director / Officer | M-Exempt | D | Performance Stock Units | 53,360 | 0.00 | — | 221,640 | D | ↗ |
| 2024-11-11 | BURNS THOMAS M. | Officer | M-Exempt | D | Performance Stock Units | 17,773 | 0.00 | — | 73,827 | D | ↗ |
| 2024-05-15 | WYSZOMIERSKI JACK L | Director | A-Award | A | Common Stock | 6,070 | 0.00 | — | 12,533 | — | ↗ |
| 2024-05-15 | PERRY MATTHEW D | Director | A-Award | A | Common Stock | 6,070 | 0.00 | — | 17,869 | — | ↗ |
| 2024-05-15 | LIMBER JOSEPH M | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 9,763 | 24.71 | 241.2K | 9,763 | — | ↗ |
| 2024-05-15 | Kosacz Barbara | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 9,763 | 24.71 | 241.2K | 9,763 | — | ↗ |
| 2024-05-15 | Hernday Natasha | Director | A-Award | A | Common Stock | 3,035 | 0.00 | — | 3,035 | — | ↗ |
| 2024-05-15 | Franklin Heather L | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 9,763 | 24.71 | 241.2K | 9,763 | — | ↗ |
| 2024-01-08 | Hughes Owen | Director / Officer | A-Award | A | Performance Stock Units | 275,000 | 0.00 | — | 275,000 | — | ↗ |
| 2023-10-03 | Sitko Bradley | Officer | P-Purchase | A | Common Stock | 250 | 13.89 | 3.5K | 5,600 | — | ↗ |
| 2023-10-02 | Sitko Bradley | Officer | P-Purchase | A | Common Stock | 1,500 | 14.25 | 21.4K | 5,350 | — | ↗ |
| 2023-10-02 | Hughes Owen | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 13.83 | 13.8K | 3,500 | — | ↗ |
| 2023-09-26 | Hughes Owen | Director / Officer | P-Purchase | A | Common Stock | 2,499 | 14.43 | 36.1K | 2,500 | — | ↗ |
| 2023-09-25 | Hughes Owen | Director / Officer | P-Purchase | A | Common Stock | 1 | 14.65 | 14.65 | 1 | — | ↗ |
| 2023-05-31 | Sitko Bradley | Officer | P-Purchase | A | Common Stock | 1,000 | 17.20 | 17.2K | 3,500 | — | ↗ |
| 2023-05-24 | Hughes Owen | Director / Officer | P-Purchase | A | Depositary Shares - 8.375% B Cumulative Stock | 1,032 | 23.79 | 24.6K | 2,000 | — | ↗ |
| 2023-05-23 | Sitko Bradley | Officer | P-Purchase | A | Common Stock | 850 | 19.00 | 16.2K | 3,850 | — | ↗ |
| 2023-05-23 | Hughes Owen | Director / Officer | P-Purchase | A | Depositary Shares - 8.375% B Cumulative Stock | 768 | 23.49 | 18.0K | 968 | — | ↗ |
| 2023-05-19 | Sitko Bradley | Officer | P-Purchase | A | Common Stock | 1,000 | 19.50 | 19.5K | 3,000 | — | ↗ |
| 2023-05-18 | Sitko Bradley | Officer | A-Award | A | Performance Stock Units | 30,200 | 0.00 | — | 30,200 | — | ↗ |
| 2023-05-18 | BURNS THOMAS M. | Officer | A-Award | A | Performance Stock Units | 91,600 | 0.00 | — | 91,600 | — | ↗ |
| 2023-05-17 | WYSZOMIERSKI JACK L | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 10,967 | 21.39 | 234.6K | 10,967 | — | ↗ |
| 2023-05-17 | PERRY MATTHEW D | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 10,967 | 21.39 | 234.6K | 10,967 | — | ↗ |
| 2023-05-17 | LIMBER JOSEPH M | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 10,967 | 21.39 | 234.6K | 10,967 | — | ↗ |
| 2023-05-17 | Kosacz Barbara | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 10,967 | 21.39 | 234.6K | 10,967 | — | ↗ |
| 2023-05-17 | Hernday Natasha | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 10,967 | 21.39 | 234.6K | 10,967 | — | ↗ |
| 2023-05-17 | Franklin Heather L | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 10,967 | 21.39 | 234.6K | 10,967 | — | ↗ |
| 2023-05-17 | BVF PARTNERS L P/IL | Director / 10% Owner | A-Award | A | Non-Qualified Stock Option (right to buy) | 10,967 | 21.39 | 234.6K | 10,967 | — | ↗ |
| 2023-05-16 | Sitko Bradley | Officer | P-Purchase | A | Depositary Shares - 8.375% B Cumulative Stock | 100 | 23.25 | 2.3K | 2,000 | — | ↗ |
| 2023-05-15 | Sitko Bradley | Officer | P-Purchase | A | Depositary Shares - 8.375% B Cumulative Stock | 1,500 | 23.40 | 35.1K | 1,500 | — | ↗ |
| 2023-05-12 | Sitko Bradley | Officer | P-Purchase | A | Common Stock | 43 | 18.66 | 802.38 | 43 | — | ↗ |
| 2023-01-06 | BVF PARTNERS L P/IL | Director | P-Purchase | A | Common Stock, $0.0075 par value per share | 1,573 | 21.98 | 34.6K | 1,618,637 | — | ↗ |
| 2023-01-05 | BVF PARTNERS L P/IL | Director | P-Purchase | A | Common Stock, $0.0075 par value per share | 3,330 | 18.39 | 61.2K | 1,788,168 | — | ↗ |
| 2023-01-03 | Sitko Bradley | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2023-01-03 | Hughes Owen | Director | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2023-01-01 | Hughes Owen | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-11-08 | BURNS THOMAS M. | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 0.00 | — | 11,000 | — | ↗ |
| 2022-09-27 | BVF PARTNERS L P/IL | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 1,004 | 16.89 | 17.0K | 1,784,838 | — | ↗ |
| 2022-09-26 | BVF PARTNERS L P/IL | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 3,339 | 16.83 | 56.2K | 1,783,834 | — | ↗ |
| 2022-09-23 | BVF PARTNERS L P/IL | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 9,885 | 16.50 | 163.1K | 1,597,695 | — | ↗ |
| 2022-09-16 | BVF PARTNERS L P/IL | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 10,897 | 17.89 | 194.9K | 1,587,810 | — | ↗ |
| 2022-09-15 | BVF PARTNERS L P/IL | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 5,575 | 17.96 | 100.1K | 1,576,913 | — | ↗ |
| 2022-09-14 | BVF PARTNERS L P/IL | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 26,441 | 17.25 | 456.0K | 1,571,338 | — | ↗ |
| 2022-07-15 | Neal James R | Director | M-Exempt | D | Stock Option (Right to Buy) | 25,000 | 0.00 | — | 218,056 | — | ↗ |
| 2022-07-15 | BURNS THOMAS M. | Director | M-Exempt | D | Stock Option (Right to Buy) | 2,000 | 0.00 | — | 75,778 | — | ↗ |
| 2022-05-18 | WYSZOMIERSKI JACK L | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 8,996 | 17.86 | 160.7K | 8,996 | — | ↗ |
| 2022-05-18 | VAN NESS W DENMAN | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 8,996 | 0.00 | — | 8,996 | — | ↗ |
| 2022-05-18 | PERRY MATTHEW D | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 8,996 | 0.00 | — | 8,996 | — | ↗ |
| 2022-05-18 | LIMBER JOSEPH M | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 8,996 | 17.86 | 160.7K | 8,996 | — | ↗ |
| 2022-05-18 | LAMPERT MARK N | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 8,996 | 0.00 | — | 8,996 | — | ↗ |
| 2022-05-18 | Kosacz Barbara | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 8,996 | 0.00 | — | 8,996 | — | ↗ |
| 2022-05-18 | Hernday Natasha | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 8,996 | 17.86 | 160.7K | 8,996 | — | ↗ |
| 2022-05-18 | Franklin Heather L | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 8,996 | 0.00 | — | 8,996 | — | ↗ |
| 2022-03-23 | Neal James R | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,111 | 4.03 | 4.5K | 102,800 | — | ↗ |
| 2022-03-22 | Neal James R | Director / Officer | M-Exempt | A | Common Stock | 2,339 | 4.03 | 9.4K | 14,161 | — | ↗ |
| 2022-03-21 | Neal James R | Director | M-Exempt | D | Stock Option (Right to Buy) | 1,111 | 0.00 | — | 102,800 | — | ↗ |
| 2022-03-21 | BURNS THOMAS M. | Director | M-Exempt | D | Stock Option (Right to Buy) | 12,000 | 0.00 | — | 18,000 | — | ↗ |
| 2022-02-22 | BURNS THOMAS M. | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 28,000 | 20.22 | 566.2K | 28,000 | — | ↗ |
| 2021-12-21 | Neal James R | Director / Officer | A-Award | A | Non-Qualified Share Option (right to buy) | 60,000 | 22.56 | 1.35M | 60,000 | — | ↗ |
| 2021-08-06 | Franklin Heather L | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 13,136 | 0.00 | — | 13,136 | — | ↗ |
| 2021-06-25 | Neal James R | Director / Officer | S-Sale | D | Common Shares | 1,171 | 34.30 | 40.2K | 12,508 | — | ↗ |
| 2021-05-19 | WYSZOMIERSKI JACK L | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 5,101 | 31.04 | 158.3K | 5,101 | — | ↗ |
| 2021-05-19 | VAN NESS W DENMAN | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 5,101 | 31.04 | 158.3K | 5,101 | — | ↗ |
| 2021-05-19 | PERRY MATTHEW D | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 5,101 | 31.04 | 158.3K | 5,101 | — | ↗ |
| 2021-05-19 | LIMBER JOSEPH M | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 5,101 | 31.04 | 158.3K | 5,101 | — | ↗ |
| 2021-05-19 | Kosacz Barbara | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 5,101 | 31.04 | 158.3K | 5,101 | — | ↗ |
| 2021-05-19 | Hernday Natasha | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 5,101 | 31.04 | 158.3K | 5,101 | — | ↗ |
| 2021-05-19 | BVF PARTNERS L P/IL | Director / 10% Owner | A-Award | A | Non-Qualified Stock Option (right to buy) | 5,101 | 31.04 | 158.3K | 5,101 | — | ↗ |
| 2021-04-09 | Neal James R | Director / Officer | A-Award | A | Depositary Shares - 8.375% B Cumulative Stock | 8,000 | 25.00 | 200.0K | 8,000 | — | ↗ |
| 2021-04-09 | BURNS THOMAS M. | Officer | A-Award | A | Depositary Shares - 8.375% B Cumulative Stock | 1,000 | 25.00 | 25.0K | 1,000 | — | ↗ |
| 2021-03-31 | BVF PARTNERS L P/IL | Director / 10% Owner | S-Sale | D | Common Stock, $0.0075 par value per share | 279,740 | 38.36 | 10.73M | 1,760,384 | — | ↗ |
| 2021-03-15 | VAN NESS W DENMAN | Director | M-Exempt | D | Non-Qualified Share Option (Right to Buy) | 3,333 | 4.03 | 13.4K | 0 | — | ↗ |
| 2021-02-17 | Neal James R | Director / Officer | A-Award | A | Non-Qualified Share Option (right to buy) | 60,268 | 38.93 | 2.35M | 60,268 | — | ↗ |
| 2021-02-17 | BURNS THOMAS M. | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 20,055 | 0.00 | — | 20,055 | — | ↗ |
| 2020-12-15 | Neal James R | Director / Officer | A-Award | A | 8.625% Series A Cumulative Perpetual Preferred Stock | 8,000 | 25.00 | 200.0K | 8,000 | — | ↗ |
| 2020-12-15 | Hernday Natasha | Director | A-Award | A | 8.625% Series A Cumulative Perpetual Preferred Stock | 4,000 | 25.00 | 100.0K | 4,000 | — | ↗ |
| 2020-12-15 | BURNS THOMAS M. | Officer | S-Sale | D | Common Stock | 9,393 | 41.02 | 385.3K | 12,162 | — | ↗ |
| 2020-12-11 | PERRY MATTHEW D | Director | P-Purchase | A | 8.625% Series A Cumulative Perpetual Preferred Stock | 200,000 | 25.00 | 5.00M | 200,000 | — | ↗ |
| 2020-12-11 | BVF PARTNERS L P/IL | Director | P-Purchase | A | 8.625% Series A Cumulative Perpetual Preferred Stock | 200,000 | 25.00 | 5.00M | 200,000 | — | ↗ |
| 2020-11-23 | Neal James R | Director / Officer | S-Sale | D | Common Stock | 13,126 | 32.96 | 432.7K | 20,849 | — | ↗ |
| 2020-11-23 | BURNS THOMAS M. | Officer | S-Sale | D | Common Stock | 5,125 | 32.93 | 168.8K | 6,555 | — | ↗ |
| 2020-11-20 | Neal James R | Director / Officer | S-Sale | D | Common Stock | 426 | 33.35 | 14.2K | 20,849 | — | ↗ |
| 2020-11-20 | BURNS THOMAS M. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,875 | 4.03 | 27.7K | 27,125 | — | ↗ |
| 2020-11-05 | Neal James R | Director / Officer | S-Sale | D | Common Stock | 9,273 | 25.90 | 240.2K | 21,576 | — | ↗ |
| 2020-11-05 | BURNS THOMAS M. | Officer | S-Sale | D | Common Stock | 7,274 | 25.98 | 188.9K | 7,281 | — | ↗ |
| 2020-09-23 | BVF PARTNERS L P/IL | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 7,201 | 18.20 | 131.1K | 1,750,704 | — | ↗ |
| 2020-09-22 | BVF PARTNERS L P/IL | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 6,960 | 18.45 | 128.4K | 2,030,236 | — | ↗ |
| 2020-09-21 | BVF PARTNERS L P/IL | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 10,069 | 18.39 | 185.1K | 1,738,512 | — | ↗ |
| 2020-09-04 | BVF PARTNERS L P/IL | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 3,907 | 18.77 | 73.3K | 2,011,017 | — | ↗ |
| 2020-09-01 | BVF PARTNERS L P/IL | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 9,900 | 18.87 | 186.8K | 2,007,110 | — | ↗ |
| 2020-08-31 | BVF PARTNERS L P/IL | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 9,143 | 18.48 | 169.0K | 1,997,210 | — | ↗ |
| 2020-08-28 | BVF PARTNERS L P/IL | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 1,122 | 19.17 | 21.5K | 1,988,067 | — | ↗ |
| 2020-08-25 | BVF PARTNERS L P/IL | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 3,443 | 19.75 | 68.0K | 1,986,945 | — | ↗ |
| 2020-08-24 | BVF PARTNERS L P/IL | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 6,504 | 19.31 | 125.6K | 1,983,502 | — | ↗ |
| 2020-08-21 | BVF PARTNERS L P/IL | Director / 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 9,198 | 19.32 | 177.7K | 1,976,998 | — | ↗ |
| 2020-08-20 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 1,772 | 19.12 | 33.9K | 1,967,800 | — | ↗ |
| 2020-08-19 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 3,496 | 19.70 | 68.9K | 1,966,028 | — | ↗ |
| 2020-08-18 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 895 | 19.27 | 17.2K | 1,962,532 | — | ↗ |
| 2020-08-14 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 21,922 | 18.69 | 409.8K | 1,961,637 | — | ↗ |
| 2020-08-13 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 1,050 | 17.80 | 18.7K | 1,939,715 | — | ↗ |
| 2020-08-12 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 4,050 | 17.34 | 70.2K | 1,938,665 | — | ↗ |
| 2020-06-30 | Hernday Natasha | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-05-20 | WYSZOMIERSKI JACK L | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 6,152 | 21.27 | 130.9K | 6,152 | — | ↗ |
| 2020-05-20 | VAN NESS W DENMAN | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 6,152 | 21.27 | 130.9K | 6,152 | — | ↗ |
| 2020-05-20 | PERRY MATTHEW D | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 6,152 | 21.27 | 130.9K | 6,152 | — | ↗ |
| 2020-05-20 | LIMBER JOSEPH M | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 6,152 | 21.27 | 130.9K | 6,152 | — | ↗ |
| 2020-05-20 | Kosacz Barbara | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 6,152 | 21.27 | 130.9K | 6,152 | — | ↗ |
| 2020-04-15 | BVF PARTNERS L P/IL | 10% Owner | C-Conversion | A | Common Stock, $0.0075 par value per share | 655,959 | 13.00 | 8.53M | 1,934,615 | — | ↗ |
| 2020-03-25 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 8,264 | 17.20 | 142.1K | 1,278,656 | — | ↗ |
| 2020-03-23 | Neal James R | Director / Officer | P-Purchase | A | Common Shares | 1,000 | 14.50 | 14.5K | 20,849 | — | ↗ |
| 2020-03-20 | Neal James R | Director / Officer | P-Purchase | A | Common Shares | 1,000 | 16.41 | 16.4K | 19,849 | — | ↗ |
| 2020-03-18 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 4,439 | 14.52 | 64.5K | 1,270,392 | — | ↗ |
| 2020-03-17 | BVF PARTNERS L P/IL | Director | P-Purchase | A | Common Stock, $0.0075 par value per share | 8,113 | 15.73 | 127.6K | 1,265,953 | — | ↗ |
| 2020-03-16 | BVF PARTNERS L P/IL | Director | P-Purchase | A | Common Stock, $0.0075 par value per share | 10,164 | 15.73 | 159.9K | 1,257,840 | — | ↗ |
| 2020-03-13 | Neal James R | Director / Officer | A-Award | A | Non Qualified Stock Option (right to buy) | 66,200 | 18.84 | 1.25M | 66,200 | — | ↗ |
| 2020-03-13 | BVF PARTNERS L P/IL | Director | P-Purchase | A | Common Stock, $0.0075 par value per share | 100,000 | 18.34 | 1.83M | 1,247,676 | — | ↗ |
| 2020-03-13 | BVF GP HOLDINGS LLC | 10% Owner | — | D | Common Stock, $0.0075 par value per share | 0 | 0.00 | — | 1,147,676 | — | ↗ |
| 2020-03-13 | BURNS THOMAS M. | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 22,000 | 18.84 | 414.5K | 22,000 | — | ↗ |
| 2019-12-23 | Neal James R | Director / Officer | X-InTheMoney | D | Subscription Rights (right to buy) | 1,180 | 22.00 | 26.0K | 0 | — | ↗ |
| 2019-12-18 | BVF PARTNERS L P/IL | Director | X-InTheMoney | A | Common Stock, $0.0075 par value per share | 190,899 | 22.00 | 4.20M | 937,353 | — | ↗ |
| 2019-11-06 | Neal James R | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,348 | 5.50 | 23.9K | 56,000 | — | ↗ |
| 2019-09-20 | Neal James R | Director / Officer | M-Exempt | A | Common Stock | 5,452 | 5.50 | 30.0K | 23,121 | — | ↗ |
| 2019-09-19 | Neal James R | Director / Officer | S-Sale | D | Common Stock | 2,642 | 21.73 | 57.4K | 17,669 | — | ↗ |
| 2019-09-19 | BURNS THOMAS M. | Officer | S-Sale | D | Common Stock | 3,671 | 21.35 | 78.4K | 7,055 | — | ↗ |
| 2019-09-18 | Neal James R | Director / Officer | S-Sale | D | Common Stock | 3,830 | 21.96 | 84.1K | 17,669 | — | ↗ |
| 2019-09-18 | BURNS THOMAS M. | Officer | M-Exempt | D | Stock Option (right to buy) | 3,829 | 4.03 | 15.4K | 46,171 | — | ↗ |
| 2019-05-16 | WYSZOMIERSKI JACK L | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 8,167 | 15.59 | 127.3K | 8,167 | — | ↗ |
| 2019-05-16 | VAN NESS W DENMAN | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 8,167 | 15.59 | 127.3K | 8,167 | — | ↗ |
| 2019-05-16 | PERRY MATTHEW D | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 8,167 | 15.59 | 127.3K | 8,167 | — | ↗ |
| 2019-05-16 | LIMBER JOSEPH M | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 8,167 | 15.59 | 127.3K | 8,167 | — | ↗ |
| 2019-05-16 | Kosacz Barbara | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 8,167 | 15.59 | 127.3K | 8,167 | — | ↗ |
| 2019-05-14 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 13,816 | 14.74 | 203.7K | 746,454 | — | ↗ |
| 2019-05-13 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 3,797 | 14.36 | 54.5K | 732,638 | — | ↗ |
| 2019-05-10 | VAN NESS W DENMAN | Director | S-Sale | D | Common Stock | 130 | 14.71 | 1.9K | 0 | — | ↗ |
| 2019-05-10 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 10,300 | 14.57 | 150.0K | 728,841 | — | ↗ |
| 2019-02-13 | Neal James R | Director / Officer | A-Award | A | Non-Qualified Share Option (right to buy) | 60,000 | 14.33 | 859.8K | 60,000 | — | ↗ |
| 2019-02-13 | DATTA DEEPSHIKHA | Officer | A-Award | A | Non-Qualified Share Option (right to buy) | 50,000 | 14.33 | 716.5K | 50,000 | — | ↗ |
| 2019-02-13 | BURNS THOMAS M. | Officer | A-Award | A | Non-Qualified Share Option (right to buy) | 23,000 | 14.33 | 329.6K | 23,000 | — | ↗ |
| 2019-01-01 | Kosacz Barbara | Director | A-Award | A | Non-Qualified Share Option (right to buy) | 19,979 | 12.65 | 252.7K | 19,979 | — | ↗ |
| 2018-12-20 | VAN NESS W DENMAN | Director | X-InTheMoney | D | Subscription Rights (right to buy) | 800 | 13.00 | 10.4K | 0 | — | ↗ |
| 2018-12-20 | Neal James R | Director / Officer | X-InTheMoney | D | Subscription Rights (right to buy) | 678 | 13.00 | 8.8K | 0 | — | ↗ |
| 2018-12-18 | BVF PARTNERS L P/IL | 10% Owner | X-InTheMoney | A | Series Y Convertible Preferred Stock | 311 | 0.00 | — | 656 | — | ↗ |
| 2018-12-17 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 25,000 | 14.19 | 354.8K | 718,541 | — | ↗ |
| 2018-12-14 | BVF PARTNERS L P/IL | 10% Owner | X-InTheMoney | A | Series Y Convertible Preferred Stock | 345 | 0.00 | — | 345 | — | ↗ |
| 2018-12-13 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 24,253 | 14.41 | 349.5K | 693,541 | — | ↗ |
| 2018-12-12 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 2,810 | 14.75 | 41.4K | 669,288 | — | ↗ |
| 2018-12-11 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 9,400 | 14.50 | 136.3K | 666,478 | — | ↗ |
| 2018-12-10 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 18,081 | 14.54 | 263.0K | 657,078 | — | ↗ |
| 2018-12-07 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 32,015 | 14.77 | 472.8K | 638,997 | — | ↗ |
| 2018-12-06 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 10,927 | 14.80 | 161.7K | 606,982 | — | ↗ |
| 2018-12-04 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 4,171 | 14.99 | 62.5K | 596,055 | — | ↗ |
| 2018-12-03 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 806 | 14.90 | 12.0K | 591,884 | — | ↗ |
| 2018-11-30 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 4,823 | 14.85 | 71.6K | 591,078 | — | ↗ |
| 2018-11-29 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 10,016 | 14.93 | 149.5K | 586,255 | — | ↗ |
| 2018-11-28 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 8,288 | 15.11 | 125.3K | 576,239 | — | ↗ |
| 2018-11-27 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0075 par value per share | 11,396 | 15.24 | 173.7K | 567,951 | — | ↗ |
Executive team
Top executives
EBIT / Employee
875.7K
Shares Outstanding
12.13M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2014 | John Varian (Chief Executive Officer) | 569.5K | — | 1.08M | 1.11M | 264.8K | 14.1K | 3.04M | 72.09% | ↗ |
| 2 | 2014 | Paul D. Rubin, M.D. (Senior Vice President, Research and Development and Chief Medical Officer) | 411.0K | — | 612.9K | 630.0K | 146.1K | 11.4K | 1.81M | 68.62% | ↗ |
| 3 | 2014 | Thomas Klein (Vice President, Chief Commercial Officer) | 391.4K | — | 387.1K | 397.9K | 150.7K | 12.9K | 1.34M | 58.58% | ↗ |
| 4 | 2014 | Fred Kurland (Vice President, Finance and Chief Financial Officer) | 347.2K | — | 387.1K | 397.9K | 124.6K | 16.3K | 1.27M | 61.66% | ↗ |
| 5 | 2014 | Patrick J. Scannon, M.D., Ph.D. (Executive Vice President and Chief Scientific Officer) | 250.3K | — | 387.1K | 397.9K | 78.8K | 18.4K | 1.13M | 69.31% | ↗ |
| 6 | 2013 | Thomas Klein (Vice President, Chief Commercial Officer) | 380.0K | — | 802.7K | 804.7K | 128.8K | 11.8K | 2.13M | 75.54% | ↗ |
| 7 | 2013 | John Varian (Chief Executive Officer) | 489.3K | — | 300.6K | 301.3K | 281.3K | 12.9K | 1.39M | 43.45% | ↗ |
| 8 | 2013 | Paul D. Rubin, M.D. (Senior Vice President, Research and Development and Chief Medical Officer) | 391.4K | — | 98.9K | 99.1K | 173.0K | 11.3K | 773.7K | 25.59% | ↗ |
| 9 | 2013 | Patrick J. Scannon, M.D., Ph.D. (Executive Vice President and Chief Scientific Officer) | 417.1K | — | 77.4K | 76.8K | 148.5K | 21.4K | 741.3K | 20.81% | ↗ |
| 10 | 2013 | Fred Kurland (Vice President, Finance and Chief Financial Officer) | 347.2K | — | 88.6K | 88.8K | 147.6K | 16.3K | 688.4K | 25.76% | ↗ |
| 11 | 2012 | Paul D. Rubin, M.D. (Senior Vice President, Research and Development and Chief Medical Officer) | 372.8K | — | 399.9K | 326.7K | 150.5K | 100.3K | 1.35M | 53.82% | ↗ |
| 12 | 2012 | Patrick J. Scannon, M.D., Ph.D. (Executive Vice President and Chief Scientific Officer) | 417.1K | — | 172.2K | 173.0K | 131.6K | 21.5K | 915.4K | 37.71% | ↗ |
| 13 | 2012 | Fred Kurland (Vice President, Finance and Chief Financial Officer) | 337.1K | — | 201.9K | 202.8K | 145.8K | 16.2K | 903.8K | 44.77% | ↗ |
| 14 | 2012 | Thomas Klein (Vice President, Chief Commercial Officer) | — | — | — | — | — | — | — | — | ↗ |
| 15 | 2010 | Steven B. Engle (Chairman of the Board, Chief Executive Officer and President) | 551.6K | — | — | 686.1K | 246.1K | 35.3K | 1.52M | 45.16% | ↗ |
| 16 | 2010 | Patrick J. Scannon, M.D., Ph.D. (Executive Vice President and Chief Scientific Officer) | 399.0K | — | — | 242.1K | 179.5K | 14.1K | 834.8K | 29.01% | ↗ |
| 17 | 2010 | Christopher J. Margolin (Vice President, General Counsel and Secretary) | 347.0K | — | — | 252.2K | 146.7K | 26.7K | 772.6K | 32.65% | ↗ |
| 18 | 2010 | Fred Kurland (Vice President, Finance and Chief Financial Officer) | 322.4K | — | — | 222.0K | 166.7K | 13.6K | 724.6K | 30.63% | ↗ |
| 19 | 2010 | Charles C. Wells (Vice President, Human Resources and Information Technology) | 312.1K | — | — | 50.4K | 132.7K | 10.5K | 505.8K | 9.97% | ↗ |
| 20 | 2009 | Steven B. Engle (Chairman of the Board, Chief Executive Officer and President) | 540.8K | — | — | 212.3K | 262.3K | 38.7K | 1.05M | 20.14% | ↗ |
| 21 | 2009 | Patrick J. Scannon, M.D., Ph.D. (Executive Vice President and Chief Medical Officer) | 389.3K | — | — | 70.8K | 123.8K | 13.1K | 597.0K | 11.85% | ↗ |
| 22 | 2009 | Patrick J. Scannon, M.D., Ph.D. (Executive Vice President and Chief Scientific Officer) | 389.3K | — | — | 70.8K | 123.8K | 13.1K | 597.0K | 11.85% | ↗ |
| 23 | 2009 | Christopher J. Margolin (Vice President, General Counsel and Secretary) | 338.5K | — | — | 70.8K | 114.8K | 28.4K | 552.4K | 12.81% | ↗ |
| 24 | 2009 | Fred Kurland (Vice President, Finance and Chief Financial Officer) | 310.0K | — | — | 70.8K | 108.7K | 12.8K | 502.2K | 14.09% | ↗ |
| 25 | 2009 | Charles C. Wells (Vice President, Human Resources and Information Technology) | 304.5K | — | — | 70.8K | 95.9K | 11.6K | 482.7K | 14.66% | ↗ |
| 26 | 2009 | Charles C. Wells (Vice President, Human Resources and Information Technology) | 304.5K | — | — | 70.8K | 95.9K | 11.6K | 482.7K | 14.66% | ↗ |
| 27 | 2008 | Steven B. Engle (Chairman of the Board, Chief Executive Officer And President) | 515.0K | — | — | 908.9K | — | 390.5K | 1.81M | 50.10% | ↗ |
| 28 | 2008 | Steven B. Engle (Chairman of the Board, Chief Executive Officer and President) | 515.0K | — | — | 243.8K | — | 390.5K | 1.15M | 21.21% | ↗ |
| 29 | 2008 | Robert S. Tenerowicz (Vice President, Operations) | 270.0K | — | — | 129.6K | — | 85.1K | 484.7K | 26.75% | ↗ |
| 30 | 2008 | Patrick J. Scannon, M.D., Ph.D. (Executive Vice President and Chief Medical Officer) | 370.8K | — | — | 86.7K | — | 17.0K | 474.5K | 18.27% | ↗ |
| 31 | 2008 | Patrick J. Scannon, M.D., Ph.D. (Executive Vice President and Chief Scientific Officer) | 370.8K | — | — | 86.7K | — | 17.0K | 474.5K | 18.27% | ↗ |
| 32 | 2008 | Christopher J. Margolin (Vice President, General Counsel and Secretary | 322.4K | — | — | 94.9K | — | 29.9K | 447.2K | 21.21% | ↗ |
| 33 | 2008 | Christopher J. Margolin (Vice President, General Counsel and Secretary) | 322.4K | — | — | 86.7K | — | 29.9K | 439.0K | 19.74% | ↗ |
| 34 | 2008 | Fred Kurland (Vice President, Finance and Chief Financial Officer) | 3.6K | — | — | 305.7K | — | — | 309.3K | 98.84% | ↗ |
| 35 | 2008 | J. David Boyle II* (Vice President, Finance and Chief Financial Officer) | 181.9K | — | — | 2.7K | — | 19.2K | 203.8K | 1.32% | ↗ |
| 36 | 2007 | Steven B. Engle (Chairman of the Board, Chief Executive Officer and President) | 202.8K | 50.0K | — | 4.57M | 112.5K | 37.0K | 4.98M | 91.92% | ↗ |
| 37 | 2007 | John L. Castello** (Chairman of the Board, President and Chief Executive Officer) | 297.4K | — | — | 539.0K | 277.4K | 71.7K | 1.19M | 45.47% | ↗ |
| 38 | 2007 | Steven B. Engle (Chairman of the Board, Chief Executive Officer And President) | 202.8K | 50.0K | — | 665.7K | 112.5K | 37.0K | 1.07M | 62.34% | ↗ |
| 39 | 2007 | Steven B. Engle* (Chairman of the Board, Chief Executive Officer And President) | 202.8K | 50.0K | — | 665.7K | 112.5K | 37.0K | 1.07M | 62.34% | ↗ |
| 40 | 2007 | Patrick J. Scannon, M.D., Ph.D. (Executive Vice President and Chief Medical Officer) | 360.0K | — | — | 461.2K | 115.6K | 17.3K | 954.1K | 48.34% | ↗ |
| 41 | 2007 | Christopher J. Margolin (Vice President, General Counsel and Secretary) | 310.0K | — | — | 367.6K | 110.0K | 29.9K | 817.6K | 44.97% | ↗ |
| 42 | 2007 | Patrick J. Scannon, M.D., Ph.D. (Executive Vice President and Chief Biotechnology Officer) | 360.0K | — | — | 92.1K | 115.6K | 17.3K | 585.0K | 15.74% | ↗ |
| 43 | 2007 | Christopher J. Margolin (Vice President, General Counsel and Secretary | 310.0K | — | — | 131.6K | 110.0K | 29.9K | 581.5K | 22.63% | ↗ |
| 44 | 2007 | Robert S. Tenerowicz (Vice President, Operations) | 256.8K | — | — | 38.9K | 84.2K | 93.7K | 473.7K | 8.21% | ↗ |
| 45 | 2007 | J. David Boyle II* (Vice President, Finance and Chief Financial Officer) | 283.0K | — | — | 42.2K | 94.3K | 1.6K | 421.2K | 10.03% | ↗ |
| 46 | 2007 | J. David Boyle II (Vice President, Finance and Chief Financial Officer) | 283.0K | — | — | 42.2K | 94.3K | 1.6K | 421.2K | 10.03% | ↗ |
| 47 | 2007 | Fred Kurland (Vice President, Finance and Chief Financial Officer) | — | — | — | — | — | — | — | — | ↗ |
| 48 | 2006 | John L. Castello** (Chairman of the Board, President and Chief Executive Officer) | 500.0K | — | 68.5K | 143.9K | 144.7K | 66.5K | 923.6K | 23.00% | ↗ |
| 49 | 2006 | Patrick J. Scannon, M.D., Ph.D. (Executive Vice President and Chief Biotechnology Officer) | 360.0K | — | 26.1K | 43.2K | 55.2K | 14.1K | 498.6K | 13.90% | ↗ |
| 50 | 2006 | Patrick J. Scannon, M.D., Ph.D. (Executive Vice President and Chief Medical Officer) | 360.0K | — | 26.1K | 43.2K | 55.2K | 14.1K | 498.6K | 13.90% | ↗ |
| 51 | 2006 | Christopher J. Margolin (Vice President, General Counsel and Secretary) | 300.0K | — | 20.1K | 57.0K | 45.1K | 27.9K | 450.1K | 17.14% | ↗ |
| 52 | 2006 | Christopher J. Margolin (Vice President, General Counsel and Secretary | 300.0K | — | 20.1K | 57.0K | 45.1K | 27.9K | 450.1K | 17.14% | ↗ |
| 53 | 2006 | Robert S. Tenerowicz (Vice President, Operations) | 247.0K | — | 15.6K | 35.6K | 40.0K | 100.7K | 439.0K | 11.67% | ↗ |
| 54 | 2006 | J. David Boyle II (Vice President, Finance and Chief Financial Officer) | 260.0K | — | 16.6K | 42.0K | 40.2K | 1.2K | 360.0K | 16.26% | ↗ |
| 55 | 2006 | J. David Boyle II* (Vice President, Finance and Chief Financial Officer) | 260.0K | — | 16.6K | 42.0K | 40.2K | 1.2K | 360.0K | 16.26% | ↗ |
| 56 | 2006 | Steven B. Engle (Chairman of the Board, Chief Executive Officer And President) | — | — | — | — | — | — | — | — | ↗ |
| 57 | 2006 | Fred Kurland (Vice President, Finance and Chief Financial Officer) | — | — | — | — | — | — | — | — | ↗ |
| 58 | 2006 | Steven B. Engle* (Chairman of the Board, Chief Executive Officer And President) | — | — | — | — | — | — | — | — | ↗ |
| 59 | 2005 | John L. Castello** (Chairman of the Board, President and Chief Executive Officer) | 500.0K | — | 51.5K | 413.4K | 108.7K | 41.0K | 1.11M | 41.70% | ↗ |
| 60 | 2005 | John L. Castello (Chairman of the Board, President and Chief Executive Officer) | 500.0K | 147.0K | — | 100.0K | — | 32.2K | 679.2K | 14.72% | ↗ |
| 61 | 2005 | Patrick J. Scannon, M.D., Ph.D. (Executive Vice President and Chief Biotechnology Officer) | 350.0K | — | 20.0K | 137.1K | 64.0K | 13.3K | 584.4K | 26.88% | ↗ |
| 62 | 2005 | Christopher J. Margolin (Vice President, General Counsel and Secretary) | 290.0K | — | 23.3K | 155.5K | 68.8K | 25.0K | 562.5K | 31.77% | ↗ |
| 63 | 2005 | Robert S. Tenerowicz (Vice President, Operations) | 227.6K | — | 16.0K | 47.0K | 37.9K | 213.9K | 542.5K | 11.62% | ↗ |
| 64 | 2005 | Patrick J. Scannon, M.D., Ph.D. (Senior Vice President and Chief Scientific and Medical Officer) | 350.0K | 120.2K | — | 30.0K | — | 11.8K | 482.0K | 6.22% | ↗ |
| 65 | 2005 | Christopher J. Margolin (Vice President, General Counsel and Secretary) | 290.0K | 98.4K | — | 55.0K | — | 11.7K | 400.0K | 13.75% | ↗ |
| 66 | 2005 | J. David Boyle II (Vice President, Finance and Chief Financial Officer) | 223.5K | 40.0K | 14.8K | 44.7K | 36.6K | 1.1K | 360.7K | 16.50% | ↗ |
| 67 | 2005 | Peter B. Davis (Retired—Vice President, Finance and Chief Financial Officer) | 145.0K | 91.2K | — | 30.0K | — | 10.3K | 246.5K | 12.17% | ↗ |
| 68 | 2005 | J. David Boyle II (Vice President, Finance and Chief Financial Officer) | 223.5K | — | — | 80.0K | — | 1.1K | 224.6K | 35.62% | ↗ |
| 69 | 2005 | Steven B. Engle* (Chairman of the Board, Chief Executive Officer And President) | — | — | — | — | — | — | — | — | ↗ |
| 70 | 2004 | John L. Castello (Chairman of the Board, President and Chief Executive Officer) | 500.0K | — | — | 100.0K | — | 30.7K | 530.7K | 18.84% | ↗ |
| 71 | 2004 | Patrick J. Scannon, M.D., Ph.D. (Senior Vice President and Chief Scientific and Medical Officer) | 340.0K | 79.1K | — | 30.0K | — | 10.8K | 430.0K | 6.98% | ↗ |
| 72 | 2004 | Peter B. Davis (Retired—Vice President, Finance and Chief Financial Officer) | 280.0K | 76.7K | — | 30.0K | — | 10.1K | 366.7K | 8.18% | ↗ |
| 73 | 2004 | Christopher J. Margolin (Vice President, General Counsel and Secretary) | 280.0K | 67.5K | — | 30.0K | — | 10.6K | 358.1K | 8.38% | ↗ |
| 74 | 2004 | J. David Boyle II (Vice President, Finance and Chief Financial Officer) | — | — | — | — | — | — | — | — | ↗ |
| 75 | 2003 | John L. Castello (Chairman of the Board, President and Chief Executive Officer) | 500.0K | — | — | 100.0K | — | 30.2K | 530.2K | 18.86% | ↗ |
| 76 | 2003 | John L. Castello (Chairman of the Board, President and Chief Executive Officer) | 500.0K | — | — | 100.0K | — | 30.2K | 530.2K | 18.86% | ↗ |
| 77 | 2003 | Patrick J. Scannon, M.D., Ph.D. (Senior Vice President and Chief Scientific and Medical Officer) | 340.0K | 69.0K | — | 30.0K | — | 9.8K | 418.8K | 7.16% | ↗ |
| 78 | 2003 | Patrick J. Scannon, M.D., Ph.D. (Senior Vice President and Chief Scientific and Medical Officer) | 340.0K | 69.0K | — | 30.0K | — | 9.8K | 418.8K | 7.16% | ↗ |
| 79 | 2003 | Clarence L. Dellio (Senior Vice President and Chief Operating Officer) | 305.0K | 47.9K | — | 40.0K | — | 9.6K | 362.6K | 11.03% | ↗ |
| 80 | 2003 | Christopher J. Margolin (Vice President, General Counsel and Secretary) | 270.0K | 56.7K | — | 50.0K | — | 9.3K | 336.0K | 14.88% | ↗ |
| 81 | 2003 | Christopher J. Margolin (Vice President, General Counsel and Secretary) | 270.0K | 56.7K | — | 50.0K | — | 9.3K | 336.0K | 14.88% | ↗ |
| 82 | 2003 | Peter B. Davis (Retired—Vice President, Finance and Chief Financial Officer) | 270.0K | 36.9K | — | 40.0K | — | 8.8K | 315.7K | 12.67% | ↗ |
| 83 | 2003 | Peter B. Davis (Vice President, Finance and Chief Financial Officer) | 270.0K | 36.9K | — | 40.0K | — | 8.8K | 315.7K | 12.67% | ↗ |
| 84 | 2003 | J. David Boyle II (Vice President, Finance and Chief Financial Officer) | — | — | — | — | — | — | — | — | ↗ |
| 85 | 2002 | John L. Castello (Chairman of the Board, President and Chief Executive Officer) | 500.0K | — | — | 50.0K | — | 31.8K | 531.8K | 9.40% | ↗ |
| 86 | 2002 | Patrick J. Scannon, M.D., Ph.D. (Senior Vice President and Chief Scientific and Medical Officer) | 340.0K | 69.2K | — | 25.0K | — | 10.4K | 419.6K | 5.96% | ↗ |
| 87 | 2002 | Clarence L. Dellio (Senior Vice President and Chief Operating Officer) | 285.8K | 67.3K | — | 55.0K | — | 8.0K | 361.2K | 15.23% | ↗ |
| 88 | 2002 | Peter B. Davis (Vice President, Finance and Chief Financial Officer) | 260.0K | 58.7K | — | 25.0K | — | 7.8K | 326.6K | 7.66% | ↗ |
| 89 | 2002 | Christopher J. Margolin (Vice President, General Counsel and Secretary) | 260.0K | 54.7K | — | 25.0K | — | 7.8K | 322.5K | 7.75% | ↗ |
| 90 | 2001 | John L. Castello (Chairman of the Board, President and Chief Executive Officer) | 500.0K | — | — | 75.0K | — | 31.4K | 531.4K | 14.11% | ↗ |
| 91 | 2001 | Patrick J. Scannon, M.D., Ph.D. (Senior Vice President and Chief Scientific and Medical Officer) | 340.0K | 64.9K | — | 25.0K | — | 12.8K | 417.6K | 5.99% | ↗ |
| 92 | 2001 | Clarence L. Dellio (Senior Vice President and Chief Operating Officer) | 273.0K | 63.5K | — | 40.0K | — | 7.3K | 343.8K | 11.64% | ↗ |
| 93 | 2001 | Peter B. Davis (Vice President, Finance and Chief Financial Officer) | 250.0K | 78.7K | — | 25.0K | — | 7.1K | 335.7K | 7.45% | ↗ |
| 94 | 2001 | Christopher J. Margolin (Vice President, General Counsel and Secretary) | 250.0K | 54.3K | — | 25.0K | — | 7.1K | 311.4K | 8.03% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Owen Hughes Jr. | Chief Executive Officer & Director | 1M | male |
| Brad Sitko | Chief Investment Officer | 853.5K | male |
| Jeffrey Trigilio | Chief Financial Officer | — | male |
| Maricel Perea Montano | Chief Legal Officer & Corporate Secretary | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for XOMA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
